功能性垂体腺瘤的药物治疗:试验与困境
本综述聚焦功能性垂体腺瘤(FPA)多模式治疗中日益重要的药物治疗角色;多数泌乳素瘤仅用药物治疗,其他FPA以经蝶手术(TSS)为一线、术后或无法手术时药物治疗为基础,新型药物仍在研究中。
要点
- 多数泌乳素瘤仅用药物治疗,部分患者可考虑在专科垂体中心行手术。
- 多巴胺激动剂尤其是卡麦角林可有效缩小肿瘤并使泌乳素正常化。
- 其他FPA以TSS为一线,多数患者需包括药物在内的复杂辅助治疗。
核心结论
- 扩大有效药物选择并增加对疗效和(或)不良反应预测因素的了解,将提高个体化治疗的可能性,不仅改善疾病控制和预后,也改善生活质量。
研究设计与样本
- 本文为小型综述(mini review),聚焦药物治疗在多模式治疗中日益重要的角色,多模式治疗还包括经蝶手术(TSS)和放疗。
主要发现
- 多数泌乳素瘤患者仅用药物治疗;多巴胺激动剂尤其是卡麦角林可有效缩小肿瘤并使泌乳素正常化。
- 对所有其他FPA,TSS为一线治疗,但多数患者需要复杂的辅助治疗,包括多种治疗方式的联合。
- 药物治疗是所有手术不成功或无法手术患者的治疗基石,包括生长抑素受体配体和多巴胺激动剂(几乎所有FPA)、生长激素受体拮抗剂(肢端肥大症)、肾上腺类固醇生成抑制剂和糖皮质激素受体阻断剂(库欣病)。
- 针对肢端肥大症和库欣病的新型药物治疗正在研究中。
临床怎么用
- 作者认为,扩大有效药物选择并增加对疗效和(或)不良反应预测因素的了解,将提高个体化治疗的可能性。
- 作者指出,药物治疗是所有手术不成功或无法手术患者的治疗基石。
- 作者指出,部分泌乳素瘤患者若治愈机会较高,可考虑在专科垂体中心行手术。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Functioning pituitary adenomas (FPAs) include most frequently prolactinomas, somatotroph or corticotroph adenomas, while thyrotroph and gonadotroph adenomas are very rare. Despite their benign histological nature (aggressive tumors are rare and malignant ones exceptional), FPAs could cause significant morbidity and increased mortality due to complications associated with hormonal excess syndromes and/or mass effect leading to compression of adjacent structures. This mini review will focus on the increasing role of medical therapy in the multimodal treatment, which also includes transsphenoidal surgery (TSS) and radiotherapy. EVIDENCE SYNTHESIS: Most patients with prolactinomas are treated only with medications, but surgery could be considered for some patients in a specialized pituitary center, if higher chances of cure. Dopamine agonists, especially cabergoline, are efficient in reducing tumor size and normalizing prolactin. TSS is the first-line treatment for all other FPAs, but most patients require complex adjuvant treatment, including a combination of therapeutic approaches. Medical therapy is the cornerstone of treatment in all patients after unsuccessful surgery or when surgery cannot be offered and includes somatostatin receptor ligands and dopamine agonists (almost all FPAs), growth hormone receptor antagonists (acromegaly), adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers (Cushing's disease). Novel medical treatments, especially for acromegaly and Cushing's disease are under research. CONCLUSIONS: An enlarged panel of effective drugs available with increased knowledge of predictive factors for response and/or adverse effects will enhance the possibility to offer a more individualized treatment. This would not only improve disease control and prognosis, but also quality of life.
引用
- Capatina C, Hanzu FA, Hinojosa-Amaya JM, et al. Medical treatment of functional pituitary adenomas, trials and tribulations. J Neurooncol. 2024. PMID: 38760632. doi:10.1007/s11060-024-04670-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。